Trials / Completed
CompletedNCT02998242
Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer
Apatinib in Combination With SBRT Treatment for Symptomatic Metastatic
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Sichuan Provincial People's Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer (SBPC), based on the potential synergistic antitumor activity between Apatinib and Stereotactic Body Radiation Therapy (SBRT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | |
| RADIATION | SBRT to symptomatic bony metastatic bony site(s) |
Timeline
- Start date
- 2016-05-10
- Primary completion
- 2017-01-05
- Completion
- 2017-12-10
- First posted
- 2016-12-20
- Last updated
- 2019-05-21
Source: ClinicalTrials.gov record NCT02998242. Inclusion in this directory is not an endorsement.